Table 3.

Change in Echocardiography and Health Status by Group

		6 month change in endpoint		ANCOVA model
Echocardiogram	N*	Vitamin D	Placebo	Vitamin D – Placebo	p-value
Ejection fraction	19, 15	0.8 ± 4.5	2.3 ± 3.5	−0.8	0.56
LV septal wall thickness	19, 15	0.0 ± 0.2	0.0 ± 0.1	0.0	0.49
LV posterior wall thickness	19, 15	0.0 ± 0.2	0.0 ± 0.1	0.1	0.25
LV mass	19, 15	−11 ± 40	−17 ± 47	−2	0.89
LV mass index	19, 15	−5 ± 19	−8 ± 21	−1	0.92
e/e’ septal mitral annulus	19, 14	−1.0 ± 5.2	−4.1 ± 8.0	1.1	0.61
Quantitative EF 4 chamber view	17, 14	−1.0 ± 13.8	10.4 ± 13.7	−3.7	0.33
Quantitative EF 2 chamber view	18, 14	1.1 ± 17.1	4.9 ± 11.4	0.9	0.84
KCCQ
Overall Summary Score	25, 27	8.9 ± 20.4	2.2 ± 13.0	6.2	0.16
Clinical Summary Score	25, 27	8.4 ± 17.0	0.3 ± 12.5	7.0	0.09
Physical limitations	25, 27	7.1 ± 18.7	1.6 ± 14.1	5.1	0.25
Total symptoms	25, 27	9.7 ± 22.8	−1.0 ± 16.7	7.5	0.15
Quality of life	25, 27	9.0 ± 28.1	4.6 ± 17.5	6.4	0.27
Social limitations	24, 27	9.9 ± 33.0	3.7 ± 19.9	5.6	0.43

^*A subset of participants was evaluated by echocardiography.

EF- ejection fraction

LV – left ventricular

KCCQ –Kansas City Cardiomyopathy Questionnaire